Bench to Bedside: Molecularly Targeted Therapies in Blood Disorders and Malignancy

Ribbon diagram of the crystal structure of BCR-ABL kinase in complex with Gleevec.

Gleevec (in red) is a drug used to treat chronic myeloid leukemia (CML). It works by inhibiting bcr-abl kinase (in green), the protein that causes CML. (Image courtesy of RCSB Protein Data Bank entry 1IEP.)

Instructor(s)

MIT Course Number

7.341

As Taught In

Fall 2009

Level

Undergraduate

Cite This Course

Course Description

Where do new drugs and treatments come from? This class will take you from the test tubes and mice of the laboratory to the treatment of patients with deadly blood disorders. Students will learn how to think as a scientist through discussion of primary research papers describing the discoveries of several novel treatments. Topics such as gene therapy, the potential of drugs based on RNA interference and the reprogramming of somatic cells into stem cells for regenerative medicine will be discussed.

This course is one of many Advanced Undergraduate Seminars offered by the Biology Department at MIT. These seminars are tailored for students with an interest in using primary research literature to discuss and learn about current biological research in a highly interactive setting. Many instructors of the Advanced Undergraduate Seminars are postdoctoral scientists with a strong interest in teaching.

Flygare, Johan, and Bill Wong. 7.341 Bench to Bedside: Molecularly Targeted Therapies in Blood Disorders and Malignancy, Fall 2009. (MIT OpenCourseWare: Massachusetts Institute of Technology), http://ocw.mit.edu/courses/biology/7-341-bench-to-bedside-molecularly-targeted-therapies-in-blood-disorders-and-malignancy-fall-2009 (Accessed). License: Creative Commons BY-NC-SA


For more information about using these materials and the Creative Commons license, see our Terms of Use.


Close